Agrees to review Moderna flu vaccine
Digest more
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Feb 18 (Reuters) - A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial,
The nasal spray works to protect the lungs of mice, and could eventually replace multiple jabs if shown to be effective and safe for humans.